Advertisement
AKBA vs CLRPF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and CLRPF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 0 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).
- AKBA’s FA Score: 0 green, 5 red.
- CLRPF’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 4 TA indicator(s) are bullish while CLRPF’s TA Score has 4 bullish TA indicator(s).
- AKBA’s TA Score: 4 bullish, 7 bearish.
- CLRPF’s TA Score: 4 bullish, 4 bearish.
Price Growth
AKBA (@Pharmaceuticals: Generic) experienced а -12.74% price change this week, while CLRPF (@Biotechnology) price change was -7.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.
Reported Earning Dates
AKBA is expected to report earnings on Mar 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+1.08% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+1.51% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AKBA | CLRPF | AKBA / CLRPF | |
| Capitalization | 466M | 987M | 47% |
| EBITDA | 11M | -78.37M | -14% |
| Gain YTD | -2.632 | 7.209 | -37% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 204M | N/A | - |
| Total Cash | 137M | 84.1M | 163% |
| Total Debt | 53.4M | N/A | - |
AKBA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 91 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AKBA | CLRPF | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 66% |
| Advances ODDS (%) | 2 days ago 85% | 17 days ago 84% |
| Declines ODDS (%) | 10 days ago 85% | 2 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TRVHX | 19.16 | 0.07 | +0.37% |
| Nuveen Mid Cap Value I | |||
| GOIOX | 34.99 | 0.11 | +0.32% |
| JHancock International Growth 1 | |||
| GWILX | 16.61 | 0.03 | +0.18% |
| Glenmede SMID Core Equity Advisor | |||
| ECCPX | 51.33 | -0.11 | -0.21% |
| Eaton Vance Tax-Managed Multi-Cap Gr C | |||
| ARREX | 26.66 | -0.27 | -1.00% |
| American Century Real Estate R5 | |||
AKBA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.
| Ticker / NAME | Correlation To AKBA | 1D Price Change % | ||
|---|---|---|---|---|
| AKBA | 100% | +2.21% | ||
| XERS - AKBA | 39% Loosely correlated | +2.02% | ||
| IPSC - AKBA | 38% Loosely correlated | N/A | ||
| SYRE - AKBA | 37% Loosely correlated | +0.34% | ||
| FENC - AKBA | 36% Loosely correlated | -1.77% | ||
| RXRX - AKBA | 36% Loosely correlated | -1.27% | ||
More | ||||
CLRPF and
Correlation & Price change
A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.
| Ticker / NAME | Correlation To CLRPF | 1D Price Change % | ||
|---|---|---|---|---|
| CLRPF | 100% | -3.33% | ||
| SBHMY - CLRPF | 24% Poorly correlated | N/A | ||
| BOLD - CLRPF | 23% Poorly correlated | -2.38% | ||
| AKBA - CLRPF | 21% Poorly correlated | +2.21% | ||
| DOSEF - CLRPF | 12% Poorly correlated | N/A | ||
| ACUT - CLRPF | 9% Poorly correlated | +1.53% | ||
More | ||||